CTKB Q1 2024 Earnings — Cytek Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CTKBCytek Biosciences, Inc.

$553M

Q1 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$45M+21.0% YoY

Gross Profit

$23M51.3% margin

Operating Income

-$11M-23.9% margin

Net Income

-$6M-13.8% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

-23.0%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

$3M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$492M

Total Liabilities

$99M

Stockholders' Equity

$393M

Cash & Equivalents

$169M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$45M	$37M	+21.0%
Gross Profit	$23M	$21M	+9.4%
Operating Income	-$11M	-$12M	+11.7%
Net Income	-$6M	-$7M	+9.4%

Revenue Segments

Service

$37M52%

Product

$34M48%

Geographic Segments

UNITED STATES

$21M48%

EMEA

$15M34%

Asia Pacific

$6M14%

Other

$2M5%